S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:COCP

Cocrystal Pharma Stock Forecast, Price & News

$1.57
-0.07 (-4.27 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.50
Now: $1.57
$1.68
50-Day Range
$1.41
MA: $1.83
$2.35
52-Week Range
$0.60
Now: $1.57
$3.04
Volume1.30 million shs
Average Volume3.86 million shs
Market Capitalization$107.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COCP
CUSIPN/A
CIKN/A
Phone786 459 1831
Employees11
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.56 million
Cash Flow$1.31 per share
Book Value$0.73 per share

Profitability

Net Income$-48,170,000.00
Net Margins-2,938.09%

Miscellaneous

Market Cap$107.65 million
Next Earnings Date3/26/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

694th out of 1,956 stocks

Pharmaceutical Preparations Industry

342nd out of 769 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.57
-0.07 (-4.27 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive COCP News and Ratings via Email

Sign-up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cocrystal Pharma (NASDAQ:COCP) Frequently Asked Questions

Is Cocrystal Pharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cocrystal Pharma stock.
View analyst ratings for Cocrystal Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Cocrystal Pharma?

Wall Street analysts have given Cocrystal Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cocrystal Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 2,450,000 shares, an increase of 21.3% from the January 14th total of 2,020,000 shares. Based on an average daily volume of 5,040,000 shares, the short-interest ratio is presently 0.5 days.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

Cocrystal Pharma is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for Cocrystal Pharma
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.07) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.03. The business earned $0.55 million during the quarter, compared to analyst estimates of $0.45 million. Cocrystal Pharma had a negative net margin of 2,938.09% and a negative trailing twelve-month return on equity of 25.81%.
View Cocrystal Pharma's earnings history
.

How has Cocrystal Pharma's stock been impacted by Coronavirus (COVID-19)?

Cocrystal Pharma's stock was trading at $1.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, COCP stock has increased by 24.6% and is now trading at $1.57.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for COCP?

2 equities research analysts have issued 12-month price objectives for Cocrystal Pharma's shares. Their forecasts range from $4.50 to $5.00. On average, they expect Cocrystal Pharma's share price to reach $4.75 in the next year. This suggests a possible upside of 202.5% from the stock's current price.
View analysts' price targets for Cocrystal Pharma
or view top-rated stocks among Wall Street analysts.

Who are Cocrystal Pharma's key executives?

Cocrystal Pharma's management team includes the following people:
  • Dr. Gary L. Wilcox, Co-Founder, Chairman & CEO (Age 74, Pay $201k)
  • Dr. Sam Lee, Co-Founder & Pres (Age 61, Pay $241k)
  • Mr. James J. Martin CPA, M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 54, Pay $231k)
  • Dr. Roger D. Kornberg, Co-Founder, Chairman of Scientific Advisory Board, Chief Scientist & Director (Age 74)

Who are some of Cocrystal Pharma's key competitors?

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Momo (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

What is Cocrystal Pharma's stock symbol?

Cocrystal Pharma trades on the NASDAQ under the ticker symbol "COCP."

Who are Cocrystal Pharma's major shareholders?

Cocrystal Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.76%), BlackRock Inc. (1.61%), Parallel Advisors LLC (0.29%), Bank of New York Mellon Corp (0.07%), Brighton Jones LLC (0.05%) and Virtu Financial LLC (0.05%).
View institutional ownership trends for Cocrystal Pharma
.

Which major investors are selling Cocrystal Pharma stock?

COCP stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Cocrystal Pharma
or view top insider-selling stocks.

Which major investors are buying Cocrystal Pharma stock?

COCP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Parallel Advisors LLC, Bank of New York Mellon Corp, HighTower Advisors LLC, and Brighton Jones LLC.
View insider buying and selling activity for Cocrystal Pharma
or or view top insider-buying stocks.

How do I buy shares of Cocrystal Pharma?

Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cocrystal Pharma's stock price today?

One share of COCP stock can currently be purchased for approximately $1.57.

How much money does Cocrystal Pharma make?

Cocrystal Pharma has a market capitalization of $107.65 million and generates $6.56 million in revenue each year. The company earns $-48,170,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Cocrystal Pharma have?

Cocrystal Pharma employs 11 workers across the globe.

What is Cocrystal Pharma's official website?

The official website for Cocrystal Pharma is www.cocrystalpharma.com.

Where are Cocrystal Pharma's headquarters?

Cocrystal Pharma is headquartered at 19805 N. CREEK PARKWAY, BOTHELL WA, 98011.

How can I contact Cocrystal Pharma?

Cocrystal Pharma's mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The company can be reached via phone at 786 459 1831 or via email at [email protected]


This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.